Policy & Regulation
Beijing Wantai plans large Phase III trial of nasal spray COVID-19 vaccine candidate
23 September 2021 -

Beijing Wantai Biological Pharmacy Enterprise (SHA:603392), a Chinese vaccine developer and manufacturer of medical products, plans to start a large trial of its nasal spray-based COVID-19 vaccine candidate next month, Reuters news agency reported on Thursday.

According to an entry posted on the Chinese Clinical Trial Registry on Wednesday, the company aims to recruit 40,000 adults for the Phase III clinical trial. Participants would be given two doses of the Beijing Wantai vaccine candidate or a placebo vaccine at a two-week interval.

The record did not specify in how many countries Beijing Wantai will run the trial. However, it indicated that an ethics committee in the Philippines had approved the study.